Two abstracts presented at the American Thoracic Society 2024 International Conference analyzed the phase 3 LIBERTY COPD BOREAS trial, finding that dupilumab improves pre- and post-bronchodilator lung function measures in patients with chronic obstructive pulmonary disease (COPD) and type 2 (T2) inflammation.